Navigation Links
Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
Date:5/2/2013

RICHMOND, Calif., May 2, 2013 /PRNewswire/ -- Lumiphore, Inc., a biotechnology leader in new proprietary bi-functional metal-chelation technology for use in targeted radiopharmaceuticals has announced that Algeta ASA (OSE:ALGETA), a company focused on the development of novel targeted cancer therapeutics, has exercised its option to take an exclusive worldwide licence to Lumiphore's patented Lumi4® bi-functional chelator technology and has extended the collaboration to include additional chelator families.  These technologies are currently being developed by Algeta to conjugate thorium-227 to tumor-targeting molecules to create Targeted Thorium Conjugates (TTCs).Lumiphore's Lumi4® technology is based on a unique class of bi-functional metal chelators1 that forms a cage structure surrounding and tightly binding thorium-227, which can then be covalently attached to a range of tumor-targeting molecules, such as monoclonal antibodies, to create cancer therapeutics.  These bi-functional chelators provide a critical component enabling payload delivery for radio-therapeutic agents.  Algeta originally signed an option/license agreement with Lumiphore around this technology in 2010 and subsequently extended it to enable further evaluation to be conducted.  This stage of evaluation has now been completed successfully.

In parallel with this license agreement, Algeta has also been granted a license by Lumiphore covering a second class of bi-functional chelators that bind strongly to thorium-227, with the option of including a further selection of compounds within that license, if future exploratory work confirms their promise.  Under the agreements, Algeta has the future potential to develop in vivo companion diagnostics for radio-imaging.

"Lumiphore's goal is to bring the benefits of bi-functional metal-chelation technology, through a variety of synthetic designs, to therapeutic markets that use targeted radiopharmaceuticals to treat cancer by the tumoricidal action of the radionuclide micro-irradiation.  The ability to chelate radioactive metal isotopes (radiotracers) and covalently attach them to therapeutic antibodies, peptides, proteins, or other receptor targeting molecules will benefit targeted delivery to cancer sites and has the potential to make current therapeutic antibodies more effective," said Dr. Ken Raymond , President and CEO of Lumiphore.  "Our technology also offers another therapeutic modality for those using antibody-drug conjugates," explained Steve Blose , Lumiphore's Chief Business Officer. He further explained that pharmaceutical companies using therapeutic antibodies could incorporate Lumiphore's technology to develop site-directed in vivo radiodiagnostics to diagnose and monitor therapeutic efficacy through radio-imaging.

Thomas Ramdahl, Algeta's Chief Technology Officer, said: "Algeta is assembling a broad portfolio of proprietary technologies (including bi-functional chelators, linkers and tumor-targeting molecules), intellectual property and expertise as a platform for generating Target Thorium Conjugates, or TTCs.  The addition of the Lumiphore technologies to the portfolio through this license and further option agreements will ensure that we have access to the best bi-functional chelators for thorium-227 as we seek to create a pipeline of TTCs designed to address multiple high-value opportunities in targeted cancer therapy."

About Lumiphore, Inc.Based in Richmond, California, Lumiphore, Inc., a privately held company, is a biotechnology leader in the development of proprietary fluorescent-metal lanthanide and chelation technology for use in high-value imaging and therapeutic applications which are commercialized through market-specific alliances with corporate partners.  Lumiphore has exclusive licenses to the basic science developed at the University of California, Berkeley in the laboratory of Professor Kenneth N. Raymond , a world expert on lanthanide and actinide chemistry.  For more information please visit www.lumiphore.com. Lumi4® is a registered mark of Lumiphore, Inc.

About AlgetaAlgeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform.  The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA).  For more information please visit www.algeta.com.

MEDIA CONTACTSFor Lumiphore, Inc.Kenneth N. Raymond, Ph.D.

President and Chairman

Tel./FAX: +510-232-8455

kraymond@lumiphore.comFor Algeta ASAMike Booth / Renate Birkeli

+47 23 00 67 32Communications & Corporate Affairs

ir@algeta.comMedia enquiries:Mark Swallow

+44 207 638 9571Citigate Dewe Rogerson

mark.swallow@citigatedr.co.ukKnut Ekern

+47 22 04 82 00Gambit Hill & Knowlton

knut.ekern@hkstrategies.com Kari Watson

+1 781 235 3060MacDougall Biomedical Communications

kwatson@macbiocom.com 1 Known as aromatic macrocyclic bi-functional chelators (AMBFs): one end binds the radionuclide/radiotracer (thorium-227) and the other end links to the tumor-targeting molecule.


'/>"/>
SOURCE Lumiphore, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
3. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
8. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
9. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
10. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
11. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... 4, 2017 OBP Medical , ... medical devices, today announced regulatory approval from ... (or Agência Nacional de Vigilância Sanitária (ANVISA)) to ... surgical retractor with integrated LED light source and ... and exposure of a tissue pocket or cavity ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/13/2017)... ... , ... “America On The Brink”: the Christian history of the United States ... creation of published author, William Nowers. Captain Nowers and his wife, Millie, have ... thirty years in the Navy. Following his career as a naval aviator and ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
Breaking Medicine News(10 mins):